We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+3.35%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
+$49.1M
Cap. Flow
+$130M
Cap. Flow %
10.05%
Top 10 Hldgs %
55.9%
Holding
47
New
6
Increased
12
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$29.3M
2
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
+$28.6M
3
SLN
Silence Therapeutics
SLN
+$20.5M
4
KALV
KalVista Pharmaceuticals
KALV
+$18.3M
5
MRUS
Merus
MRUS
+$15.8M

Top Sells

Rank Stock Value
1
TRIL
Trillium Therapeutics Inc.
TRIL
+$55M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$20.4M
3
BLU
BELLUS Health Inc.
BLU
+$2.65M
4
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
+$1.95M
5
FRLN
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
+$1.88M

Sector Composition

Rank Sector Weight
1 Healthcare 98.85%
2 Miscellaneous 1.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TYRA icon
26
Tyra Biosciences
TYRA
$1.56B
$17.6M 1.35%
1,250,000
– –
KALV
27
DELISTED
KalVista Pharmaceuticals
KALV
$17.3M 1.33%
1,305,087
+1,148,280
+732% +$18.3M
TCDA
28
DELISTED
Tricida, Inc. Common Stock
TCDA
$17.1M 1.31%
+1,783,893
New +$11.5M
COGT icon
29
Cogent Biosciences
COGT
$6.44B
$15.2M 1.17%
+1,774,891
New +$15.4M
FLACU
30
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$14.9M 1.15%
1,501,000
– –
ARVN icon
31
Arvinas
ARVN
$604M
$13.5M 1.04%
+163,763
New +$13.3M
GRCL
32
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$10M 0.77%
1,654,938
+803,300
+94% +$7.72M
EPIX
33
DELISTED
ESSA Pharma
EPIX
$7.72M 0.59%
543,470
+185,124
+52% +$2.06M
RGNX icon
34
Regenxbio
RGNX
$619M
$7.71M 0.59%
235,809
– –
AVDL
35
DELISTED
Avadel Pharmaceuticals
AVDL
$7.69M 0.59%
951,814
– –
ACRS icon
36
Aclaris Therapeutics
ACRS
$907M
$5.94M 0.46%
408,329
– –
MTEM
37
DELISTED
Molecular Templates, Inc.
MTEM
$5.39M 0.41%
91,603
– –
APTX
38
DELISTED
Aptinyx Inc. Common Stock
APTX
$5.03M 0.39%
1,883,244
– –
IMVT icon
39
Immunovant
IMVT
$9.05B
$4.99M 0.38%
585,759
– –
SRRK icon
40
Scholar Rock
SRRK
$7.22B
$3.88M 0.3%
156,000
– –
EPZM
41
DELISTED
Epizyme, Inc
EPZM
$1.85M 0.14%
739,369
– –
ALNA
42
DELISTED
Allena Pharmaceuticals
ALNA
$978K 0.08%
1,651,357
-1,679,016
-50% -$1.31M
NBRV
43
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$255K 0.02%
17,026
– –
GRTX
44
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
– –
-241,000
Closed -$1.95M
FRLN
45
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
– –
-36,667
Closed -$1.88M
BLU
46
DELISTED
BELLUS Health Inc.
BLU
– –
-433,247
Closed -$2.65M
TRIL
47
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-3,123,107
Closed -$55M
1
2

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q4 2021 Portfolio in Review

As of Q4 2021, Frazier Management held 47 positions worth $1.3B, up 3.9% from $1.25B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Frazier Management deployed $130M of net new capital in Q4 2021, opening 6 new positions and adding to 12 existing holdings. Its largest new stake was Pardes Biosciences, Inc. Common Stock: 2,457,507 shares worth $40.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $20.4M trimmed.

  • Frazier Management's largest Q4 2021 buy was Pardes Biosciences, Inc. Common Stock: 2,457,507 shares worth $40.2M.
  • Frazier Management added most to Syndax Pharmaceuticals in Q4 2021, an estimated $29.3M increase.
  • Frazier Management's biggest Q4 2021 reduction was Iovance Biotherapeutics, cutting an estimated $20.4M.
  • Frazier Management fully exited Trillium Therapeutics Inc. in Q4 2021, selling an estimated $55M.
  • Frazier Management's ten largest holdings make up 56% of its $1.3B portfolio in Q4 2021.
  • Frazier Management opened 6 new positions and closed 4 in Q4 2021.
  • Frazier Management's portfolio value rose 3.9% quarter-over-quarter to $1.3B.

Based on Frazier Management's 13F filing for Q4 2021, filed 8 Feb 2022.